Latuda

Lurasidone, the active ingredient in Latuda, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia and for depressive episodes associated with bipolar I disorder in adult patients.

GNH USA supplies Latuda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under strict quality‑assured processes.

Lurasidone (Latuda) is employed in the management of serious psychiatric conditions within the psychotic and mood disorder spectrum.

- Schizophrenia: reduces psychotic symptoms and helps prevent relapse in adult patients. - Bipolar I disorder (depressive episodes): alleviates depressive symptoms and improves overall mood stability. - Maintenance treatment of schizophrenia: supports long‑term symptom control.

Common Side Effects: - Nausea - Akathisia (restlessness) - Somnolence or insomnia - Headache - Weight gain - Dizziness

Serious or Rare Side Effects: - Tardive dyskinesia - Neuroleptic malignant syndrome - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behaviours - Metabolic disturbances such as hyperglycaemia

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly. - Metabolic monitoring: check weight, glucose and lipid levels periodically. - Suicidality assessment: evaluate for depressive symptoms and suicidal ideation, especially early in treatment. - Cardiac evaluation: consider ECG monitoring in patients with known QT prolongation. - Hepatic function: use caution and adjust dose in moderate to severe hepatic impairment. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Lurasidone may interact with several concomitant medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lurasidone exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Monoamine oxidase inhibitors (MAOIs): risk of additive CNS effects.

Moderate Interactions (Monitor Closely):\n- Other antipsychotics or dopamine‑modulating agents: increased risk of extrapyramidal symptoms. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation. - QT‑prolonging drugs (e.g., certain antiarrhythmics, fluoroquinolones): monitor cardiac rhythm.